Stryker Corporation $SYK Shares Bought by Nicholas Company Inc.

Nicholas Company Inc. grew its position in shares of Stryker Corporation (NYSE:SYK) by 31.8% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 216,873 shares of the medical technology company’s stock after purchasing an additional 52,345 shares during the quarter. Stryker makes up about 1.2% of Nicholas Company Inc.’s holdings, making the stock its 27th largest position. Nicholas Company Inc.’s holdings in Stryker were worth $68,280,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Brighton Jones LLC boosted its position in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the period. Schnieders Capital Management LLC. acquired a new position in Stryker during the second quarter worth approximately $205,000. Marshall Wace LLP increased its position in Stryker by 107.9% during the second quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after buying an additional 77,831 shares during the period. Nebula Research & Development LLC purchased a new stake in Stryker in the second quarter valued at approximately $219,000. Finally, HUB Investment Partners LLC purchased a new stake in Stryker in the second quarter valued at approximately $253,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Down 0.7%

NYSE:SYK opened at $338.80 on Friday. Stryker Corporation has a 12-month low of $281.00 and a 12-month high of $396.86. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. The stock’s 50 day simple moving average is $324.61 and its 200-day simple moving average is $333.57. The firm has a market cap of $129.95 billion, a P/E ratio of 35.11, a PEG ratio of 2.16 and a beta of 0.76.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.58 billion. During the same period last year, the company earned $3.13 earnings per share. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities analysts anticipate that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. Stryker’s dividend payout ratio is presently 36.48%.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the transaction, the director directly owned 1,924,880 shares in the company, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the stock. Citigroup restated a “buy” rating on shares of Stryker in a research report on Thursday. Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a research report on Friday, May 1st. Canaccord Genuity Group decreased their price target on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Robert W. Baird set a $385.00 price objective on shares of Stryker in a research report on Friday, May 1st. Finally, BMO Capital Markets initiated coverage on shares of Stryker in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.